Curevo Vaccine is a biotechnology company based in Seattle, specializing in the development of next-generation subunit vaccines for diseases of global health importance. The company’s lead vaccine candidate, CRV 101, is currently under investigation for its safety, tolerability, immunogenicity, and effectiveness in preventing Shingles in older adults. CRV 101 has successfully completed a Phase 1 clinical trial in healthy adults and is now being evaluated for its potential use in immunocompromised children to prevent chickenpox.

Curevo Vaccine operates in the biotech sector, primarily serving healthcare providers, research institutions, and public health organizations. The company’s business model revolves around extensive research and development, clinical trials, and eventual commercialization of its vaccine candidates. Revenue is generated through partnerships, grants, and future sales of approved vaccines.

Keywords: subunit vaccines, biotechnology, Shingles prevention, chickenpox prevention, clinical trials, immunogenicity, safety, tolerability, global health, Seattle.